![Pascale Augé](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Pascale Augé
Direktor/Vorstandsmitglied bei
Laboratoire Français du Fractionnement et des Biotechnologies
Profil
Pascale Augé currently works at Laboratoire Français du Fractionnement et des Biotechnologies, as Director, INSERM Transfert Initiative SAS, as Director, Linkinvax SA, as Director, and eureKING SA, as Independent Director from 2022.
Dr. Augé also formerly worked at INSERM Transfert SA, as Chairman-Management Board from 2014 to 2025, Ernst & Young Audit SAS (France), as Senior Manager from 2004 to 2011, AB Science SA, as Project Manager from 2003 to 2004, and Novachim SA, as Project Manager.
Aktive Positionen von Pascale Augé
| Unternehmen | Position | Beginn |
|---|---|---|
Laboratoire Français du Fractionnement et des Biotechnologies
 Laboratoire Français du Fractionnement et des Biotechnologies Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets plasma-derived medicinal products & recombinant proteins for the treatment of patients | Direktor/Vorstandsmitglied | - |
Linkinvax SA
 Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform | Direktor/Vorstandsmitglied | - |
eureKING SA
 eureKING SA Financial ConglomeratesFinance Operates as a special purpose acquisition company | Direktor/Vorstandsmitglied | 05.05.2022 |
INSERM Transfert Initiative SAS
 INSERM Transfert Initiative SAS Investment ManagersFinance Acts as Venture Capital Fund | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Pascale Augé
| Unternehmen | Position | Ende |
|---|---|---|
INSERM Transfert SA
 INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions. | Vorstandsvorsitzender | 05.09.2025 |
Ernst & Young Audit SAS (France)
 Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Provides Auditing & Accounting Services | Corporate Officer/Principal | 01.01.2011 |
| AB SCIENCE | Corporate Officer/Principal | 01.01.2004 |
Novachim SA | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
44
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
INSERM Transfert SA
INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions. | Finance |
Ernst & Young Audit SAS (France)
Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Provides Auditing & Accounting Services | Commercial Services |
Laboratoire Français du Fractionnement et des Biotechnologies
Laboratoire Français du Fractionnement et des Biotechnologies Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets plasma-derived medicinal products & recombinant proteins for the treatment of patients | Health Technology |
INSERM Transfert Initiative SAS
INSERM Transfert Initiative SAS Investment ManagersFinance Acts as Venture Capital Fund | Finance |
AB Science SA
 AB Science SA Pharmaceuticals: OtherHealth Technology Provides biochemical research services | Health Technology |
Linkinvax SA
Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform | Commercial Services |
eureKING SA
eureKING SA Financial ConglomeratesFinance Operates as a special purpose acquisition company | Finance |
Novachim SA |
